References
- Grosse SD. Assessing cost–effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev. Pharmacoecon. Outcomes Res. 8(2), 165–178 (2008).
- McCabe C, Claxton K, Culyer AJ. The NICE cost–effectiveness threshold: what it is and what that means. Pharmacoeconomics 26(9), 733–744 (2008).
- Stinnett AA, Paltiel AD. Mathematical programming for the efficient allocation of health care resources. J. Health Econ. 15(5), 641–653 (1996).
- Garber AM, Phelps CE. Economic foundations of cost–effectiveness analysis. J. Health Econ. 16(1), 1–31 (1997).
- Meltzer D. Accounting for future costs in medical cost–effectiveness analysis. J. Health Econ. 16(1), 33–64 (1997).
- Detsky AS, Naglie IG. A clinician’s guide to cost–effectiveness analysis. Ann. Intern. Med. 113(2), 147–154 (1990).
- Jena AB, Philipson TJ. Endogenous cost–effectiveness analysis and health care technology adoption. J. Health Econ. 32(1), 172–180 (2013).
- Devlin N, Parkin D. Does NICE have a cost–effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 13(5), 437–452 (2004).
- Milgrom P. Auctions and bidding: a primer. J. Econ. Perspect. 3(3), 3–22 (1989).
- Basu A. Individualization at the heart of comparative effectiveness research: the time for I-CER has come. Med. Decis. Making 29(6), NP9–NP11 (2009).
- Basu A. Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care. J. Health Econ. 30(3), 549–559 (2011).
Website
- Claxton K, Martin S, Soares M et al. Methods for the estimation of the NICE cost–effectiveness threshold. www.york.ac.uk/che/research/teehta/methodological-research/#tab-4 (Accessed 1 November 2012)